89 results about "Targeted liposomes" patented technology

The invention belongs to the technical field of medicine, and discloses an active targeting atherosclerotic plaque liposome and application thereof in diagnosis, a carrier material for forming the liposome comprises targeting peptide R8 modified methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), polypropylene sulfide-polyethylene glycol (PPS-PEG) and cholesterol (CH), and the targeting peptide R8 modified methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), the polypropylene sulfide-polyethylene glycol (PPS-PEG) and the cholesterol (CH) are combined to form the active targeting atherosclerotic plaque liposome. The sequence of the targeting peptide R8 is Asp-Ser-Ser-Ser-Gln-Cys-His-Arg, and the sequence of the targeting peptide R8 is Asp-Ser-Ser-Gln-Cys-His- The liposome provided by the invention can improve the enrichment concentration of a fluorescent dye or a drug in local lesion, and has the advantages of low toxicity and high efficiency, and the obtained targeted liposome has a good effect on diagnosis of atherosclerosis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

Targeting liposomes for protein degrader delivery. In one embodiments, the targeting liposome including a phospholipid, a cholesterol or cholesterol derivative, a PEG lipid, a targeting lipid; and a protein degrader. In other embodiments, the targeting liposome including a phospholipid, a cholesterol or cholesterol derivative, a PEG lipid, a targeting lipid; and a protein degrader- ligase complex. Also provided are kits for preparing targeting liposomes for protein degrader and / or protein degrader-ligase complexes. Also provided are methods for preparing such targeting liposomes.

The invention relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, and the functionalized targeted liposome comprises lipid and a targeted ligand, wherein the targeting ligand can be specifically combined with a TREM2 receptor. According to the lipidosome, the targeting ligand can be specifically combined with the TREM2 receptor, accurate targeting of cells with the surface containing the TREM2 receptor is achieved, it is ensured that the cells directly act on target cells, the accuracy of a delivered substance is further improved, and the lipidosome has the advantages of being targeting, high in stability, small in side effect and high in bioavailability. The functionalized targeted liposome can be applied to the development of drug carriers, pharmaceutical compositions and the like, and has wide application prospects, for example, the liposome is dynamically connected with hydrogel molecules through a borate bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome, and the application prospect is wide. The liposome disclosed by the invention can respond to an inflammatory environment according to pH and ROS changes of a surrounding environment to release the liposome disclosed by the invention, targets cells with TREM2 receptors on the surfaces, namely microglial cells (with the TREM2 receptors on the surfaces) by virtue of the target ligands exposed on the surfaces, regulates the polarization state of the cells, inhibits the polarization of the cells to a pro-inflammatory M1 type and promotes the polarization of the cells to an anti-inflammatory M2 type, so that the anti-inflammatory effect of the liposome is improved. Therefore, the local microenvironment of the spinal cord injury part is improved, and nerve regeneration is promoted.

The present invention belongs to the field of medical technology, and discloses a liposome that actively targets atherosclerotic plaques and its application in diagnosis. The carrier material forming the liposome includes a targeting peptide R8 modified with methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), polysulfide propylene-polyethylene glycol (PPS-PEG) and cholesterol (CH), and the sequence of the targeting peptide R8 is Asp-Ser-Ser-Ser-Gln-Cys-His-Arg. The liposome of the present invention can increase the enrichment concentration of fluorescent dyes or drugs in the local lesion, has the advantages of low toxicity and high efficiency, and the obtained targeted liposome has a good effect on the diagnosis of atherosclerosis.

The invention relates to an exosome fusion liver targeting liposome drug delivery system as well as a preparation method and application thereof, and belongs to the field of high polymer material science and pharmaceutical preparations. The invention discloses an exosome-fused liver-targeted liposome drug delivery system, which combines high-concentration PEG8000 and Nycodenz in a breakthrough manner, synergistically improves the fusion efficiency of exosome and liposome, and forms bionic vesicles with uniform size and high drug loading capacity. The exosome not only can exert the anti-inflammatory and anti-oxidation characteristics, but also plays a role in resisting a severe gastrointestinal environment and crossing a biological barrier. In addition, liposome is modified by cholic acid derivatives through EDC / NHS mediated amidation reaction, precise targeting of the liver is achieved, and the liposome is fully accumulated in the liver. The effects synergistically realize the treatment of type II diabetes and non-alcoholic steatohepatitis.

The invention belongs to the technical field of medicine, and discloses a sea cucumber and ganoderma lucidum immune steady-state compound and a composite enzymatic hydrolysis targeted liposome co-delivery preparation process thereof.The sea cucumber and ganoderma lucidum immune steady-state compound is composed of sea cucumber, ganoderma lucidum, American ginseng, dried oyster meat, fructus lycii and perilla leaves; the ganoderma triterpenes release free polysaccharides and are combined with a liposome intestinal targeted delivery system, so that the absorption rate of the polysaccharides is greatly improved to 18-22% from 5% in the traditional process, the ganoderma triterpenes are emulsified and entrapped through a liposome double-layer membrane, and meanwhile, the permeation promotion effect of perillaldehyde in the perilla leaf volatile oil is supplemented, so that the transmembrane transport efficiency is remarkably enhanced, the absorption rate is improved to 12-15% from 2%, and the bioavailability is improved. The zinc element decomposes oyster zinc protein into free zinc ions through a composite enzymolysis technology, and the free zinc ions and vitamin C form a stable chelate, so that the antagonism of intestinal tracts is reduced, the zinc absorption rate is increased from 20% to 45-50%, and a solid foundation is laid for fully playing a compound immune regulation effect.

The invention discloses an emulsifier for preparing a Pickering emulsion, the Pickering emulsion as well as a preparation method and application of the Pickering emulsion. The emulsifier of the Pickering emulsion is obtained by dissolving distearoyl phosphatidylcholine, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 in ethanol, carrying out rotary evaporation to remove ethanol, then adding an antigen aqueous solution containing an antigen, continuing rotary evaporation to obtain liposome nanoparticles, heating the liposome nanoparticles with mannose in a water bath, and carrying out freeze drying. The Pickering emulsion is obtained by dispersing an emulsifier in water as a water phase, taking squalene as an oil phase, mixing the water phase and the oil phase, and homogenizing. The Pickering emulsion disclosed by the invention is prepared by taking antigen presenting cell targeted liposome nanoparticles as a raw material; and the antigen has excellent ion concentration characteristic, pH stability, temperature stability and storage stability, and can protect the integrity of the antigen.

A nanoparticle generally comprising a targeting peptide-lipid conjugate, wherein a targeting peptide moiety of the targeting peptide-lipid conjugate comprises a GRP78 targeting peptide, a polyethylene glycol (PEG)-lipid conjugate, a drug-lipid conjugate comprising a prodrug moiety, wherein the drug-lipid conjugate comprises one or more of a mertansine (DM1) prodrug, a doxorubicin prodrug, and a bortezomib (BTZ) prodrug; and wherein the prodrug is linked to a lipid moiety of the drug-lipid conjugate via a phosphodiester bond or a boron ester bond; cholesterol comprising about 1 mol% to about 10 mol% of the nanoparticle; and distearoylphosphatidylcholine (DSPC).

The invention relates to a brain-targeted stilbene glucoside and tanshinone IIA loaded combined liposome for treating Alzheimer's disease and improving learning and memory ability disorders and a preparation method thereof. The composition comprises a modification factor Angiopep-2, a liposome carrier, stilbene glucoside and tanshinone IIA. Angiopep-2 is used as a target head, and a film dispersion and ammonium sulfate gradient method is adopted to prepare the liposome. According to the present invention, the problems of poor solubility and low bioavailability of stilbene glucoside and tanshinone IIA are solved, and the Angiopep-2 and the blood brain barrier (BBB) surface LRP-1 are subjected to specific recognition and are combined to enter the brain, such that the blood brain barrier transmittance of the drug is increased, and the targeting ability of the drug is improved. The traditional Chinese medicine composition has a good application prospect in the aspects of treating the Alzheimer's disease and improving learning and memory dysfunction.

The present disclosure provides an actively encapsulated liposome nanocarrier delivery system. The liposome nanocarrier delivery system includes a liposome carrier and substances actively encapsulated thereby for use in preventing and / or treating atherosclerosis or diseases related to atherosclerosis. The preparation of the nanocarrier delivery system includes the step of adding a saline solution that causes an acidity gradient of a liposome solution inside and outside of a body so as to hydrate the substances actively encapsulated by the liposome carrier for use in preventing and / or treating atherosclerosis or diseases related to atherosclerosis. Further provided are a preparation method for the liposome nanocarrier delivery system and an application thereof.

The invention relates to an asparagine endopeptidase inhibitor neuronal targeting liposome and a preparation method thereof. The liposome comprises the following components: lecithin, cholesterol, phospholipid polyethylene glycol polypeptide, a fluorescent dye and an asparagine endopeptidase inhibitor. The preparation method has relatively good drug loading capacity and entrapment efficiency; after being atomized and dosed through a nose, the nebulizer can smoothly enter the brain of a mouse through a blood brain barrier to be distributed, and has good biocompatibility; according to the invention, DNA damage and ROS reaction of irradiated brain neurons and glial cells can be reduced, and the research and development value and important academic significance of the liposome for assisting in improving radiation brain injury are revealed.

The invention provides an auxiliary analysis method, device and equipment for a neural circuit injury position and a medium, and relates to the field of medical image processing, and the method comprises the steps: obtaining whole brain sample data, including fMRI data and DTI data of a healthy sample and a tested sample; selecting a seed point based on the fMRI data, establishing whole brain function connection based on the seed point, and extracting a time-varying connection coefficient sequence between the seed point and the region of interest; based on the DTI data, determining a connection fiber between the seed point and the region of interest through probabilistic fiber tracking, obtaining a target liposome representing the connection fiber and a surrounding region thereof, and obtaining a white matter bold signal sequence of the target liposome; and performing difference analysis on the connection coefficient sequence and the white matter bold signal sequence of the healthy sample and the tested sample to obtain the abnormal voxel of the tested sample, and determining the neural circuit injury position according to the coordinate of the abnormal voxel, thereby providing important information for the research of neural activity.

The application discloses a method for modifying phospholipids and application thereof in preparation of liver-targeted liposomes, relates to the field of drug delivery, and first utilizes cholate and mannose to modify phospholipid molecules DSPE-PEG 2000 respectively 2000 Two raw materials DSPE-PEG 2000 -CA and DSPE-PEG 2000 -MAN for synthesizing liposomes are synthesized, and then cholesterols, DSPC and DC-cholesterols are added in a certain proportion to obtain liposomes with liver targeting property, which have high cell safety and liver cell targeting property.

Methods and compositions for the treatment of viral infections, such as HIV infection, are disclosed herein. In certain embodiments, a molecular conjugate comprising a viral capture domain and an immunostimulant molecule is provided.

This disclosure relates to a targeted PEGylated liposomal gemcitabine (PLG) composition comprising a PEGylated liposome encapsulating one or more agents comprising gemcitabine and a targeting moiety; pharmaceutical composition and methods comprising PLG or producing PLG; and manufacturing equipment for performing the methods.

The application discloses a liver-targeting lipid carrier as well as a preparation method and application thereof, relates to the field of drug delivery, and utilizes cholate and mannose to respectively modify a phospholipid molecule DSPE-PEG 2000 After two raw materials DSPE-PEG-CA and DSPE-PEG-MAN composed of synthetic liposomes are obtained, the liver-targeting lipid carrier is obtained according to a certain proportion of cholesterol, DSPC, DC-cholesterol and the like, and the liposome has high cell safety and liver targeting.

A preparation method of a liposome encapsulating a polypeptide, suberoylanilide hydroxamic acid (SAHA), and vitamin A is provided, including the following steps: dissolving choline, cholesterol, an anti-angiogenic lytic peptide, the SAHA, and the vitamin A in a chloroform-methanol solution and mixing evenly, and subjecting an obtained mixed solution to spin drying under reduced pressure to form a film; and subjecting the film to hydration with a phosphate-buffered saline (PBS) solution or ddH2O to obtain the liposome. Use of the preparation method is further provided, where a liposome prepared by the preparation method is used as a drug for treating hepatic fibrosis. An “anti-hepatic fibrosis drug” is combined with “liver-targeted vitamin A” to construct a “target liposome encapsulating the anti-hepatic fibrosis drug”.

The invention discloses a drug molecular structure-based liposome construction recommendation method and device, and the method comprises the steps: receiving the molecular information of a target drug inputted by a user, and carrying out the data preprocessing of the molecular information; and then, recommendation is performed based on the standard molecular feature data through a pre-trained liposome recommendation model. And finally, optimizing the construction parameters based on the target liposome construction type to obtain target liposome construction parameters. According to the method, the constructed liposome structure type is recommended based on the drug molecule information through the pre-trained neural network model, and the construction parameters of the liposome are optimized to obtain the optimal liposome construction parameters. The molecular structure characteristics of the drug are directly associated with a liposome construction scheme, and the efficiency and accuracy of liposome construction are improved.

The invention provides a synthesis method and a synthesis device of lipidosome, and the method comprises the following steps: respectively introducing two liquids of an organic phase and a water phase into two sample introduction channels of a Y-shaped flow channel; the Y-shaped flow channel comprises the two sample introduction channels and a synthesis channel communicated with the convergence position of the two sample introduction channels; and driving a regular pentagonal special ultrasonic device arranged at the bottom of the synthesis channel to work, and mixing the two liquids in the synthesis channel at least through micro vortexes which are generated in the liquids in the synthesis channel and are distributed at the positions of the edges of the regular pentagon when the special ultrasonic device works, so as to generate the target liposome. Through collaborative design of the micro-channel structure and the special ultrasonic device, the synthesis efficiency of the lipidosome can be remarkably improved, and the average particle size and uniformity of a product in the synthesis process of the lipidosome are optimized.

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

The invention discloses a targeted liposome and application thereof, a targeted liposome preparation and a preparation method and application thereof, and relates to the technical field of biology.The targeted liposome is prepared from, by mole, 50%-55% of distearoyl phosphatidylcholine, 30%-35% of cholesterol, 4%-6% of phosphatidyl glycerol, 7%-8% of DSPE-PEG2000 and 0.3%-0.6% of DSPE-PEG2000-targeted peptide, and the targeting peptide in the DSPE-PEG2000-targeting peptide comprises at least one of an ANG2 peptide, a Tf peptide and an ApoE peptide. According to the application, the targeted liposome crosses the blood brain barrier, and efficient release of drug molecules aiming at brain glioma cells is realized.

The invention relates to the technical field of biological medicine, and particularly discloses a lipidosome targeting SELENOP + macrophages, a preparation method of the lipidosome and application of the lipidosome in lung squamous cell carcinoma treatment. According to the lipidosome, an SELENOP antibody is used as a targeted modification molecule, si-SELENOP and s-ABCA1 / G1 are loaded, and accurate delivery of siRNA in target cells is achieved through specific binding of the antibody and a SELENOP receptor on the surface of a SELENOP + macrophage. The targeting liposome prepared by the invention can specifically inhibit cholesterol efflux pathways of SELENOP + macrophages, reverse tumor phenotypic polarization, remodel a tumor immune microenvironment and recover anti-tumor activity of immune cells such as CD8 + T cells, NK cells and the like. When the liposome is independently used or combined with a PD-1 antibody, the growth and metastasis of the lung squamous cell carcinoma can be remarkably inhibited, the treatment effect is improved, a brand new metabolism-immunity synergistic targeted treatment strategy is provided for the lung squamous cell carcinoma, and the liposome has a good clinical application prospect.

The invention discloses a breast-dredging and stasis-removing health-care cream and a preparation method thereof. The breast-dredging and stasis-removing health-care cream is composed of active components such as a ranunculus ternatus alcohol extract, panax notoginseng saponins, radix bupleuri volatile oil and the like, and an emulsion matrix. Through targeted liposome modification and a temperature-sensitive slow release technology, efficient delivery of anti-hyperplasia components is realized, the cream has dual effects of reducing the volume and relieving pain on breast nodules, and the transdermal efficiency is improved by 210% compared with that of traditional cream.

The invention belongs to the technical field of medicines, and particularly relates to a brain-targeted liposome for delivering mRNA (messenger ribonucleic acid) as well as a preparation method and application of the brain-targeted liposome. The liposome ingeniously utilizes the similar structure of PMPC and acetylcholine, can efficiently pass through BBB and target brain and hippocampus, and realizes personalized accurate delivery of mRNA to realize safe and effective prevention and treatment of brain diseases. The preparation method of the liposome comprises the following steps: (1) synthesizing PMPC-CPADN; (2) synthesizing DSPE-PMPC (Distearoyl Pyrrolidone- (3) preparation of lipidosome: mixing SM-102, DSPC, cholesterol, DSPE-PMPC and DMG-PEG (Dimethyl Glycol-Polyethylene Glycol) according to a certain molar ratio to prepare a lipidosome solution; the lipidosome can be used for preparing the lipidosome / mRNA compound, and the lipidosome / mRNA compound can be used for preparing medicines for treating brain diseases. The PMPC modified brain-targeted liposome for delivering mRNA is stable in physicochemical property, effectively protects mRNA from being degraded by nuclease, and can load mRNA and deliver the mRNA to the brain.

The application belongs to the technical field of medicine, and relates to preparation and application of a liposome prodrug overcoming adriamycin resistance. 2000 On the basis, the prodrug is loaded in a constructed targeted liposome (DSPE-PEG The preparation method is simple, the stability is good, high-efficiency drug loading and delivery are realized, and the liposome prodrug is stable, slow-released, safe, and the like. The liposome prodrug can target the folate receptor on the surface of a tumor, under the action of high-level GSH in a tumor cell, the disulfide bond is broken and BQR and DOX are released. BQR can induce tumor cell ferroptosis and hinder DNA repair, and can synergistically kill tumor cells with adriamycin while overcoming cell resistance to adriamycin. The liposome prodrug prepared in the application realizes targeted delivery of drugs, has good in-vitro anti-tumor activity, overcomes adriamycin resistance, and has a broad development prospect.

A novel liposome-targeted delivery cream containing ectoine and ceramide and its application, mainly used for relieving skin problems such as skin sensitivity, dermatitis, eczema, etc.; the novel liposome combines soybean lecithin, cholesterol, polyethylene glycol-targeting ligand, and the targeting ligand is ectoine to prepare a targeted liposome capable of simultaneously connecting and encapsulating hydrophilic ectoine and hydrophobic ceramide; further added to the cream matrix to develop a novel liposome-targeted delivery cream of compound ectoine combined with ceramide; it has a phospholipid bilayer and is self-closed in structure, can encapsulate ceramide inside the liposome, has good stability, and at the same time stably connects and modifies water-soluble ectoine to prevent its rapid degradation and reduce the drug release rate. Adding it to the cream matrix and directly applying it to the required skin area can achieve targeted transport of the drug in the skin tissue.

A natural immune agonist complex, consisting of an immune agonist and a targeted liposome, where the immune agonist is M(cGAMP)Ln. The targeted liposome is formed by a nanobody targeting a tumor microenvironment, a cell membrane-targeted penetrating peptide, or a blood-brain barrier-targeted penetrating peptide with a liposome through chemical bonding. This application further provides a preparation and application of the natural immune agonist complex.

The present application relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, comprising: lipids and a targeting ligand; wherein the targeting ligand can specifically bind to a TREM2 receptor. The liposome of the present application can specifically bind to the TREM2 receptor by means of the targeting ligand, realize precise targeting of cells containing the TREM2 receptor on the surface, ensure direct action on target cells, and further improve the precision of delivered substances. The liposome has targeting property, high stability, small side effects, and can be applied to the development of drug carriers, pharmaceutical compositions, etc., and has a wide application prospect. For example, the liposome of the present application is dynamically connected with a hydrogel molecule by a borate ester bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome of the present application. The hydrogel pharmaceutical composition can release the liposome of the present application according to the change of pH and ROS in the surrounding environment in response to an inflammatory environment, and target cells containing the TREM2 receptor on the surface, i.e. microglial cells (having the TREM2 receptor on the surface), by virtue of the targeting ligand exposed on the surface, and regulate the polarization state of the cells, inhibit the polarization of the cells to the pro-inflammatory M1 type, and promote the polarization of the cells to the anti-inflammatory M2 type, thereby improving the local microenvironment of the spinal cord injury site and promoting nerve regeneration.